Lifetime risk of liver‐related outcomes and determinants in male inactive carriers of chronic hepatitis B

医学 肝细胞癌 内科学 人口 肝硬化 乙型肝炎 队列 乙型肝炎表面抗原 乙型肝炎病毒 免疫学 病毒 环境卫生
作者
Wan‐Jung Wu,Chih‐Lin Lin,Chun‐Jen Liu,Yi‐Wen Huang,Jui‐Ting Hu,Ming‐Whei Yu
出处
期刊:Journal of Medical Virology [Wiley]
卷期号:95 (10) 被引量:1
标识
DOI:10.1002/jmv.29138
摘要

The full spectrum of risks for the life course of inactive hepatitis B virus (HBV) carriers remains unclear. In this study, 995 untreated HBV carriers (median age: 42.8 years; median follow-up: 30.2 years) were included. Their data were sourced from a population-based cohort study of male civil servants recruited in 1989-1992. Outcomes were identified by active follow-up examinations and linkage with national health insurance research database. At baseline, 483 subjects were inactive carriers, 385 with indeterminate phase, and 127 with other phases. The joint lifetime risk for incident cirrhosis, decompensation, hepatocellular carcinoma, and liver-related deaths was lower for inactive carriers compared to subjects in other phases (p < 0.0001). There was a trend of increase in incidence among inactive carriers; the 5-, 10-, and 20-year cumulative incidences were 1.86%, 6.03%, and 10.07%, respectively. Of the inactive carriers, 37.7% cleared HBsAg and 36.6% had biochemical relapse during the study. Biochemical relapse, obesity, and advanced age were predictors for disease progression in inactive carriers. Virological relapse was the predominant cause of biochemical relapse. Higher HBV-DNA levels (≥1000 copies/mL or 200 IU/mL) and HBV genotype B (vs. C) were associated with higher virological relapse rate. After 30 years, we found that one-time measure of inactive carrier state continued to have the lowest risk compared with other infection phases. Despite a more favorable prognosis, inactive carriers had a non-negligible risk. Our findings of lifetime risk may provide important clues for the management of such patients and consideration of therapeutic strategies aiming to achieve functional cure.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小马甲应助lili采纳,获得10
刚刚
1秒前
2秒前
彭凯发布了新的文献求助10
2秒前
Ava应助李点点采纳,获得10
2秒前
4秒前
jxp完成签到,获得积分10
4秒前
r41r32完成签到 ,获得积分10
4秒前
5秒前
5秒前
秋水浮萍发布了新的文献求助10
6秒前
lili给lili的求助进行了留言
8秒前
一杯沧海完成签到 ,获得积分10
10秒前
12秒前
脑洞疼应助李点点采纳,获得10
12秒前
橘又青应助高不二采纳,获得10
13秒前
爱静静应助Charles采纳,获得30
14秒前
ding应助执光采纳,获得10
14秒前
无花果应助lfl采纳,获得10
16秒前
赘婿应助xxxx采纳,获得10
17秒前
科研通AI2S应助Billy采纳,获得10
20秒前
24秒前
future完成签到 ,获得积分10
25秒前
25秒前
李加威完成签到 ,获得积分10
27秒前
可ke完成签到 ,获得积分10
27秒前
PhD_Lee73完成签到 ,获得积分10
27秒前
在水一方应助朱朱采纳,获得10
28秒前
桐桐应助李点点采纳,获得10
28秒前
lili发布了新的文献求助10
28秒前
xudongmei发布了新的文献求助10
30秒前
清爽完成签到,获得积分10
32秒前
Jessiez94完成签到,获得积分10
33秒前
HNDuan发布了新的文献求助50
34秒前
34秒前
杨婷婷发布了新的文献求助10
40秒前
今后应助李点点采纳,获得10
40秒前
小高同学完成签到,获得积分10
41秒前
一蓑烟雨任平生应助123采纳,获得10
42秒前
科研通AI2S应助Charles采纳,获得10
43秒前
高分求助中
Licensing Deals in Pharmaceuticals 2019-2024 3000
Cognitive Paradigms in Knowledge Organisation 2000
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger Heßler, Claudia, Rud 1000
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 1000
Natural History of Mantodea 螳螂的自然史 1000
A Photographic Guide to Mantis of China 常见螳螂野外识别手册 800
How Maoism Was Made: Reconstructing China, 1949-1965 800
热门求助领域 (近24小时)
化学 医学 材料科学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 量子力学 冶金 电极
热门帖子
关注 科研通微信公众号,转发送积分 3318402
求助须知:如何正确求助?哪些是违规求助? 2949819
关于积分的说明 8548151
捐赠科研通 2626513
什么是DOI,文献DOI怎么找? 1437229
科研通“疑难数据库(出版商)”最低求助积分说明 666193
邀请新用户注册赠送积分活动 652133